Related Experiment Videos
Gene therapy for lysosomal storage diseases.
1Department of Pathology, Washington University School of Medicine, St Louis, MO 63110, USA.
Expert Opinion on Investigational Drugs
|July 5, 2005
Summary
Lysosomal storage diseases result from enzyme deficiencies, causing cellular buildup. Gene therapy offers a promising treatment approach by addressing the underlying genetic defects.
Area of Science:
- Biochemistry
- Genetics
- Molecular Biology
Background:
- Lysosomal storage diseases (LSDs) are inherited disorders caused by single lysosomal enzyme deficiencies.
- These diseases lead to progressive intralysosomal storage and affect approximately 1 in 3,000 live births, with variable severity.
- Current treatments are limited to supportive care and genetic counseling.
Purpose of the Study:
- To describe the biochemical and molecular basis of gene therapy for LSDs.
- To provide an overview of in vitro and in vivo studies on gene therapy for LSDs.
Main Methods:
- Review of existing literature on gene therapy strategies for LSDs.
- Analysis of biochemical and molecular mechanisms underlying gene therapy approaches.
- Summary of findings from in vitro and in vivo experimental studies.
Main Results:
- Gene therapy holds potential for treating LSDs by correcting the enzymatic defects.
- Numerous in vitro and in vivo studies demonstrate the feasibility and efficacy of gene therapy for various LSDs.
- Advances in gene transfer and expression technologies are crucial for successful gene therapy implementation.
Conclusions:
- Gene therapy represents a viable therapeutic strategy for lysosomal storage diseases.
- Further research and clinical translation are needed to fully realize the potential of gene therapy for LSDs.
- Understanding the genetic basis of LSDs is key to developing effective gene-based treatments.